MicroRNA‑206 suppresses proliferation and predicts poor prognosis of HR‑HPV-positive cervical cancer cells by targeting G6PD

Cui,Jinpeng; Pan,Yinghua; Wang,Jianhua; Liu,Yan; Wang,Hongyan; Li,Hongyan

doi:10.3892/ol.2018.9326

MicroRNA‑206 suppresses proliferation and predicts poor prognosis of HR‑HPV-positive cervical cancer cells by targeting G6PD

Authors:
- Jinpeng Cui
- Yinghua Pan
- Jianhua Wang
- Yan Liu
- Hongyan Wang
- Hongyan Li
View Affiliations

Affiliations: Laboratory Medicine, Yantaishan Hospital, Yantai, Shandong 264000, P.R. China, Imaging Department, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China, Laboratory Medicine, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China, Department of Health Management, People's Hospital of Zhangqiu District, Jinan, Shandong 250200, P.R. China, Department of Obstetrics, People's Hospital of Zhangqiu District, Jinan, Shandong 250200, P.R. China, Department of Outpatient, People's Hospital of Weifang, Weifang, Shandong 261000, P.R. China
Published online on: August 20, 2018 https://doi.org/10.3892/ol.2018.9326
Pages: 5946-5952
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer (CC) is one of the most frequent gynecological malignancies in females worldwide. Aberrant expression of microRNA (miR)‑206 was reported to play an important role in tumor progression. The aim of the present study was to evaluate the potential role of miR‑206 and verify its influence on the function of glucose‑6‑phosphate dehydrogenase (G6PD) in CC. Western blot analysis and RT‑PCR were employed to measure miR‑206 and G6PD expression. Luciferase assays were performed to validate G6PD as miR‑206 targets. CCK‑8 assay was performed to examine the regulation of miR‑206 and G6PD on CC proliferation. The result showed that miR‑206 was downregulated, while G6PD was upregulated in high risk human papillomavirus (HR‑HPV)(+) CC. miR‑206 directly targeted the 3'‑UTR of G6PD. miR‑206 overexpressed or G6PD low-expressed suppressed cell proliferation. miR‑206 low expressed or G6PD overexpressed predicted poor prognosis. In conclusion, miR‑206 reduced cancer growth and suppresses the G6PD expression in CC. This newly identified miR‑206 may provide further insight into tumor progression and offers a promising target for the CC therapy.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Munagala R, Kausar H, Munjal C and Gupta RC: Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis. 32:1697–1705. 2011. View Article : Google Scholar : PubMed/NCBI
3	Zur Hausen H: Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2:342–350. 2002. View Article : Google Scholar : PubMed/NCBI
4	Moody CA and Laimins LA: Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer. 10:550–560. 2010. View Article : Google Scholar : PubMed/NCBI
5	Woodman CB, Collins SI and Young LS: The natural history of cervical HPV infection: Unresolved issues. Nat Rev Cancer. 7:11–22. 2007. View Article : Google Scholar : PubMed/NCBI
6	Wang X, Wang HK, McCoy JP, Banerjee NS, Rader JS, Broker TR, Meyers C, Chow LT and Zheng ZM: Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA. 15:637–647. 2009. View Article : Google Scholar : PubMed/NCBI
7	Hu T, Li YS, Chen B, Chang YF, Liu GC, Hong Y, Chen HL and Xiyang YB: Elevated glucose-6-phosphate dehydrogenase expression in the cervical cancer cases is associated with the cancerigenic event of high-risk human papillomaviruses. Exp Biol Med (Maywood). 240:1287–1297. 2015. View Article : Google Scholar : PubMed/NCBI
8	Salimi A, Paeezi M, Yousefsani BS, Shadnia S, Hassanian-Moghaddam H, Zamani N and Pourahmad J: Inhibition of glucose-6-phosphate dehydrogenase protects hepatocytes from aluminum phosphide-induced toxicity. Pestic Biochem Physiol. 143:141–146. 2017. View Article : Google Scholar : PubMed/NCBI
9	Polat MF, Taysi S, Gul M, Cikman O, Yilmaz I, Bakan E and Erdogan F: Oxidant/antioxidant status in blood of patients with malignant breast tumour and benign breast disease. Cell Biochem Funct. 20:327–331. 2002. View Article : Google Scholar : PubMed/NCBI
10	Hu T, Zhang C, Tang Q, Su Y, Li B, Chen L, Zhang Z, Cai T and Zhu Y: Variant G6PD levels promote tumor cell proliferation or apoptosis via the STAT3/5 pathway in the human melanoma xenograft mouse model. BMC Cancer. 13:2512013. View Article : Google Scholar : PubMed/NCBI
11	Pes GM, Bassotti G and Dore MP: Colorectal cancer mortality in relation to glucose − 6 - phosphate dehydrogenase deficiency and consanguinity in Sardinia: A spatial correlation analysis. Asian Pac J Cancer Prev. 18:2403–2407. 2017.PubMed/NCBI
12	Giatromanolaki A, Sivridis E, Arelaki S and Koukourakis MI: Expression of enzymes related to glucose metabolism in non-small cell lung cancer and prognosis. Exp Lung Res. 43:167–174. 2017. View Article : Google Scholar : PubMed/NCBI
13	Hu T, Chang YF, Xiao Z, Mao R, Tong J, Chen B, Liu GC, Hong Y, Chen HL, Kong SY, et al: miR-1 inhibits progression of high-risk papillomavirus-associated human cervical cancer by targeting G6PD. Oncotarget. 7:86103–86116. 2016. View Article : Google Scholar : PubMed/NCBI
14	Ambros V and Lee RC: Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning. Methods Mol Biol. 265:131–158. 2004.PubMed/NCBI
15	Gimpel C, Avni FE, Bergmann C, Cetiner M, Habbig S, Haffner D, König J, Konrad M, Liebau MC, Pape L, et al: Perinatal diagnosis, management, and follow-up of cystic renal diseases: A clinical practice recommendation with systematic literature reviews. JAMA Pediatr. 172:74–86. 2018. View Article : Google Scholar : PubMed/NCBI
16	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
17	Pan X, Wang Z, Wan B and Zheng Z: MicroRNA-206 inhibits the viability and migration of medulloblastoma cells by targeting LIM and SH3 protein 1. Exp Ther Med. 14:3894–3900. 2017. View Article : Google Scholar : PubMed/NCBI
18	Pang C, Huang G, Luo K, Dong Y, He F, Du G, Xiao M and Cai W: miR-206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9. Cancer Med. 6:2398–2409. 2017. View Article : Google Scholar : PubMed/NCBI
19	Liu F, Zhao X, Qian Y, Zhang J, Zhang Y and Yin R: MiR-206 inhibits head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. Biomed Pharmacother. 96:229–237. 2017. View Article : Google Scholar : PubMed/NCBI
20	FIGO Committee on Gynecologic Oncology, . FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet. 125:97–98. 2014. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
23	Rob L, Halaska M and Robova H: Nerve-sparing and individually tailored surgery for cervical cancer. Lancet Oncol. 11:292–301. 2010. View Article : Google Scholar : PubMed/NCBI
24	Pandima Devi K, Rajavel T, Daglia M, Nabavi SF, Bishayee A and Nabavi SM: Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer. Semin Cancer Biol. 46:146–157. 2017. View Article : Google Scholar : PubMed/NCBI
25	Muluhngwi P and Klinge CM: Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer. Mol Cell Endocrinol. 456:76–86. 2017. View Article : Google Scholar : PubMed/NCBI
26	Chuanyin L, Xiaona W, Zhiling Y, Yu Z, Shuyuan L, Jie Y, Chao H, Li S, Hongying Y and Yufeng Y: The association between polymorphisms in microRNA genes and cervical cancer in a Chinese Han population. Oncotarget. 8:87914–87927. 2017. View Article : Google Scholar : PubMed/NCBI
27	Manikandan J, Aarthi JJ, Kumar SD and Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs in understanding cancer. Bioinformation. 2:330–334. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yin K, Yin W, Wang Y, Zhou L, Liu Y, Yang G, Wang J and Lu J: MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells. Oncotarget. 7:24537–24548. 2016.PubMed/NCBI
29	Yan B, Zhu CD, Guo JT, Zhao LH and Zhao JL: miR-206 regulates the growth of the teleost tilapia (Oreochromis niloticus) through the modulation of IGF-1 gene expression. J Exp Biol. 216:1265–1269. 2013. View Article : Google Scholar : PubMed/NCBI
30	Ling S, Ruiqin M, Guohong Z, Bing S and Yanshan C: Decreased microRNA-206 and its function in cervical cancer. Eur J Gynaecol Oncol. 36:716–721. 2015.PubMed/NCBI
31	Gao LP, Cheng ML, Chou HJ, Yang YH, Ho HY and Chiu DT: Ineffective GSH regeneration enhances G6PD-knockdown Hep G2 cell sensitivity to diamide-induced oxidative damage. Free Radic Biol Med. 47:529–535. 2009. View Article : Google Scholar : PubMed/NCBI